Translational and transformative myeloid cancer pathology and research
We strive to provide novel and more objective genomic and proteomic tests, in order to detect myeloid cancer earlier and to better inform treatment. Moreover, by understanding how cancers manipulate the innate immune environment, we hope to discover novel biomarkers and treatment targets. By applying this knowledge, our goal is to provide more personalized diagnosis and care.
Next-generation sequencing, NanoString-based nucleic acid expression analysis (gene/mRNA, miRNA, lncRNA, DNA copy number, gene fusions, ChIP-string), multi-fluorescence flow cytometry
- Healthcare and social services
- Life sciences, pharmaceuticals and medical equipment
Specialized labs and equipment
|
Equipment |
Function |
|---|---|
|
NanoString nCounter Analysis System |
Digital nucleic acid expression |
|
Miltenyi MACSQuant Flow Cytometer |
Multi-fluorescence flow cytometer |
Private and public sector research partners
- Queen’s University
- TRtech
- Micralyne Inc.
- Université de Montréal (dont le Centre de Coordination des Essais Cliniques de Montréal (MHICC) et l'Institut de Recherches Cliniques de Montréal(IRCM))
- Génome Canada
- Génome Québec
- Washington University School of Medicine
- Ontario Institute for Cancer Research